logo

Stemline Therapeutics Inc (STML)



Trade STML now with
  Date
  Headline
8/8/2019 10:38:38 PM Stemline Therapeutics Prices Underwritten Public Offering Of 5 Mln Shares At $15.25/shr
8/2/2019 7:12:29 AM Stemline Therapeutics Q2 Net Loss $16.8 Mln; Net Revenue For ELZONRIS $13.0 Mln
6/17/2019 7:37:48 AM Stemline Therapeutics Announces Presentation Of ELZONRIS Preclinical Data In Systemic Sclerosis At EULAR Congress
6/13/2019 7:37:13 AM Stemline Therapeutics Announces Three ELZONRIS Clinical Presentations At EHA Congress
5/13/2019 6:55:15 AM Wedbush Is Increasing Stemline Therapeutics Inc (STML) FY19 Rev. Estimate To 37.2 M From 31.8 M
5/13/2019 6:55:02 AM Wedbush Is Increasing Stemline Therapeutics Inc (STML) Q4 19 Rev. Estimate To 12.5 M From 10.8 M
5/13/2019 6:54:50 AM Wedbush Is Raising Stemline Therapeutics Inc (STML) Q3 19 Rev. Estimate To 10.7 M From 9.1 M
5/13/2019 6:54:37 AM Wedbush Is Increasing Stemline Therapeutics Inc (STML) Q2 19 Rev. Estimate To 8.9 M From 7.6 M
5/13/2019 6:54:14 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) FY19 Estimate To -2.21 From -1.81
5/13/2019 6:53:51 AM Wedbush Is Cutting Stemline Therapeutics Inc (STML) Q4 19 Estimate To -0.47 From -0.42
5/13/2019 6:53:38 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) Q3 19 Estimate To -0.49 From -0.44
5/13/2019 6:53:23 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) Q2 19 Estimate To -0.51 From -0.45
5/13/2019 6:52:50 AM Wedbush Downgrades Stemline Therapeutics Inc (STML) To Neutral From Outperform With $18 Price Target
5/10/2019 6:33:27 AM Stemline Therapeutics Q1 Net Loss $27.4 Mln; Net Revenue For ELZONRIS $5.05 Mln
1/30/2019 7:36:36 AM Stemline Therapeutics Announces Validation Of MAA By The European Medicines Agency (EMA)
1/18/2019 11:28:13 AM Stemline Therapeutics Closes $92 Mln Public Offering Of Common Stock
1/15/2019 10:07:24 PM Stemline Therapeutics Prices Public Offering Of 8.89 Mln Shares At $9.00/shr
1/14/2019 4:36:41 PM Stemline Therapeutics Announces Proposed Public Offering Of Common Stock